Better Health for All

Revvity's core business is dedicated to improving health outcomes through diagnostics and life sciences. The company is committed to newborn screening and rare disease awareness, aiming for early detection and intervention for conditions affecting millions globally.

Its advanced screening technologies, including genome sequencing, have identified risks for pediatric-onset diseases in 8.2% of apparently healthy newborns, enabling early interventions. Revvity also provides solutions to accelerate clinical trials and has partnered to expand sickle cell disease screening in sub-Saharan Africa to reduce mortality rates. No products with negative health impacts were identified. The company is not involved in food production or products with addiction potential.

Fair Money & Economic Opportunity

Revvity Inc. is a life sciences and diagnostics company, not a financial services provider.

The company's core business involves providing solutions for drug discovery, diagnostics, and research. As such, it does not offer lending, deposit services, or other financial products to consumers. Therefore, all KPIs related to financial services, consumer credit, and financial inclusion are not applicable to its business model.

Fair Pay & Worker Respect

As of December 29, 2024, approximately 36.36% of Revvity's 11,000 global employees were covered by labor unions and workers’ councils’ agreements.

The voluntary employee turnover rate for fiscal year 2024 was approximately 9%. In 2023, the company achieved a 75% employee satisfaction rate from its People Experience Survey, which saw 85% participation. Revvity states it offers competitive compensation and benefits, including health insurance, and benchmarks market practices. Many of its large manufacturing sites are ISO 45001 and 14001 certified for health and safety. In 2023, women comprised approximately 40% of leadership positions (director level and above), and the company expanded its audited gender pay gap analysis.

Fair Trade & Ethical Sourcing

Revvity Inc. has implemented a Sustainability Due Diligence Program covering most of its annual direct material supplier spend, as highlighted in its 2024 Impact Report.

A sustainable procurement policy was introduced in 2023, emphasizing ethical sourcing practices. Revvity's Supplier Code of Conduct prohibits child labor, forced labor, and discrimination, ensuring fair wages, safe working conditions, and compliance with environmental and anti-corruption laws. The company filed Conflict Minerals Reports for 2022 and 2023, detailing due diligence processes aligned with OECD Guidance. These processes involve surveying over 1,150 direct and sub-tier suppliers to identify and mitigate risks associated with conflict minerals.

Honest & Fair Business

Revvity Inc. has an S&P Global ESG Score of 43.

The company has an anti-corruption compliance policy that is FCPA-compliant and applies to third-party intermediaries and suppliers, requiring them to complete relevant training and disclose violations. The Audit Committee monitors compliance with this policy. A whistleblower policy is in place, establishing procedures for the receipt, retention, and confidential, anonymous submission and treatment of complaints regarding accounting, internal accounting controls, or auditing matters, and an ethics hotline is available. More than a majority of the board members are independent, with 6 out of 7 mentioned directors being independent, representing approximately 85.7% of the board. The Audit Committee oversees the qualifications, independence, and performance of the independent registered public accounting firm, including assessing its independence annually and reviewing its quality-control reports. The Human Capital Committee also retains an independent consultant and assesses its independence.

Kind to Animals

Revvity has adopted an Animal Welfare Policy and a Bioethics Policy.

The company leverages high-content screening solutions, IVIS in vivo imaging systems, and 3D cell culture models to maximize information per animal and reduce test subjects. It also develops technologies for animal-free solutions and explores new approach methodologies (NAMs) such as cell-based assays, 3D organoids, organ-on-a-chip technologies, and in-silico modeling to reduce reliance on animal models. Revvity supports the National Center for the Replacement, Refinement and Reduction of Animals in Research. The company also endorses the FDA Modernization Act 2.0, which permits alternative models to animal studies.

No War, No Weapons

Revvity's government contracts, including a $9.26 million award for the MARTY project, pertain to health science solutions and do not indicate involvement in military or defense-related activities.

The company rebranded in April 2023 to focus exclusively on life sciences and diagnostics. The board's Audit Committee oversees the Enterprise Risk Management framework, including supply chain and human rights risks. In 2025, the company had $160,000 in lobbying expenditures for the Pharmaceuticals/Health Products industry. Revvity has been a signatory to the UN Global Compact since 2008. The SoBC affirms Revvity’s longstanding commitment to universal principles, including the 10 Principles of the UNGC, which encompasses human rights, labor standards, environmental protection, and anti-corruption, achieving a 98% on-time completion rate in 2024. The company also issues an annual Modern Slavery and Human Trafficking Statement. For conflict minerals, approximately 15% of components most likely to contain conflict minerals do, in fact, contain them, based on 2024 data.

Planet-Friendly Business

Revvity is committed to Science Based Targets initiative (SBTi) emission reduction targets and intends to submit them for verification in 2025 or 2026.

In 2024, 43% of the company's total electricity consumed was sourced from renewables. The company diverted 49% of non-hazardous waste from landfills in 2024, surpassing its 2027 goal of 40%.

Respect for Cultures & Communities

Revvity Inc. has reported no incidents of cultural appropriation.

The company also states that Free, Prior and Informed Consent (FPIC) processes are not applicable to its operations, as its documents do not specify projects impacting Indigenous Peoples.

Safe & Smart Tech

Revvity Inc. demonstrates strong data security through compliance with industry standards, including SOC 2 Type 2 and ISO27001 certifications

, with its Transcribe AI service operating within an ISO27001-compliant framework . The company also maintains a HIPAA Privacy Policy, outlining its obligations to protect personal health information and ensuring compliance with healthcare regulations . Revvity has not identified risks from known cybersecurity threats, including any prior cybersecurity incidents, that have materially affected its operations, business strategy, results of operations, or financial condition , and has a Material Cyber Incident Disclosure Program with preventative measures .

Zero Waste & Sustainable Products

Revvity Inc. achieved a 49% non-hazardous waste diversion rate in 2024, surpassing its 2027 goal of 40%.

The company has set a company-wide target to achieve a 40% non-hazardous waste landfill diversion rate by 2027. Numerous waste reduction initiatives are in place, including enhanced recycling programs, chemical and process substitutions, and site-specific projects. Notably, the Lafayette, CO site achieved a 100% reduction in solid hazardous waste and a 69.8% reduction in solvent waste, while the Euroimmun Mexico City team reduced hazardous waste by 57%. Revvity also complies with the EU RoHS and REACH directives. The company has a sustainability due diligence program covering 60% of annual direct material supplier spend, supported by a Supplier Code of Conduct and an EcoVadis partnership. Furthermore, Revvity provides customers with environmental safety information for proper product handling and instructions on avoiding releases of Annex XIV substances. The company is compliant with the EU WEEE Directive, offering take-back options where legally required.